Global Pegfilgrastim Biosimilars Market

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products. The main types of biosimilar monoclonal antibodies market are synthetic chemicals, biopharmaceuticals and others. Any pharmaceutical drug product made in, derived from, or semi-synthesized from biological sources is known as a biopharmaceutical, sometimes known as a biologic medical product, or biologic. The different compounds include infliximab, rituximab, abciximab, trastuzumab, adalimumab, bevacizumab and is used in various applications such as chronic and autoimmune diseases, oncology, others. The global biosimilar monoclonal antibodies market size is expected to grow from $4.51 billion in 2021 to $5.47 billion in 2022 at a compound annual growth rate (CAGR) of 21.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar monoclonal antibodies market is expected to reach $10.64 billion in 2026 at a CAGR of 18.1%. The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American cancer society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases including cancer is expected to drive the biosimilar monoclonal antibodies market. Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the biosimilar monoclonal antibodies market. The governments of different regions impose different rules regarding the production and use of biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars, only 7 biosimilars including 4 originating biologics could enter the US commercial market. The strict government policies for approval of these drugs negatively impact manufacturers in the biosimilar monoclonal antibodies market. The focus areas for many companies in the biosimilar monoclonal antibodies market has shifted to mergers and acquisitions to acquire more production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities, or to gain access to new markets. For instance, Aurobindo Pharma Limited acquired four cell culture-derived biosimilar products from TL Biopharmaceutical AG of Switzerland. As part of the agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. Out of the four biosimilars acquired, three of them are monoclonal antibodies in oncology. In another instance, in May 2020, AbbVie, a US-based biopharmaceutical company, announced its decision to acquire Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies. Allergan is an Ireland-based pharmaceutical company that manufactures, develops, and markets drugs, biosimilars, medical devices, eye care, and others. Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics and Intas Pharmaceuticals Limited. The regions covered in the biosimilar MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar monoclonal antibodies market is segmented - 1) By Type: Synthetic Chemicals, Biopharmaceuticals, Others 2) By Application: Chronic and Autoimmune Diseases, Oncology, Others 3) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

The biosimilar therapeutic peptides market consists of sales of biosimilar therapeutic peptides by the companies that are engaged in developing and commercialization of biosimilar peptides drugs for therapeutic applications. Peptide drugs are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease. Biosimilar therapeutic peptides find its application in the treatment of cardiovascular diseases, metabolic diseases, respiratory conditions, cancer, and respiratory diseases. The main types of biosimilar therapeutic peptides market are innovative and generic. Biosimilar medications are frequently mistaken for generic drugs. Both are marketed as low-cost knockoffs of high-priced name-brand medications. The main distinction is that generics are duplicates of synthetic pharmaceuticals, whereas biosimilars are based on drugs that contain biological organisms as active components. The different routes of administration include parenteral route, transdermal route, others and is used in cancer, cardiovascular, central nervous systems, metabolic disorders, infection, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders. The global biosimilar therapeutic peptides market size is expected to grow from $0.93 billion in 2021 to $1.21 billion in 2022 at a compound annual growth rate (CAGR) of 30.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar therapeutic peptides market is expected to reach $3.50 billion in 2026 at a CAGR of 30.3%. The increasing aging population is projected to surge the patients with chronic diseases contributing to the biosimilar therapeutic peptides market growth. Elderly people are more prone to various chronic diseases, surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 years is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the 2019 Revision, the number of people aged 80 years and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides market are used for the treatment of various chronic diseases and cancer. The expected increase in the aging population suffering from various chronic conditions will drive the biosimilar market. The long and costly drug approval process is expected to limit the growth of the biosimilar therapeutic peptides market over the upcoming years. The development, approval, and launch of new drugs is an expensive and prolonged procedure that includes expensive research stages. A new drug has to go through four phases of clinical trials and screening by the regulatory body including Food and Drug Administration (FDA) (USA), Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), and Medicines and Healthcare Products Regulatory Agency (MHRA) (India). According to a report of Tufts Center for the Study of Drug Development published by the Journal of Health Economics in 2019, a cost to develop new drugs is $2.6 billion whereas the approval rate for drugs entering clinical trail is less than 12%. Therefore, long and costly drug approvals of new drug candidates are anticipated to hinder the growth of biosimilar therapeutic peptides market. During the forecast period, biosimilar therapeutic peptides market is expected to witness a growth in research collaborations as well as research funding approvals. Key companies are focusing on collaborations with companies and organizations to enhance their research & developments, expand their product portfolio, and geographical reach. For instance, in January 2020, a UK-based biotechnology company focusing on developing a class of therapeutics based on its proprietary bicyclic peptide technology announced a collaboration with Cancer Research UK to develop BT7401, a new bicycle immune-oncology candidate. Cancer Research UK will fund and sponsor the development of a new candidate. In addition to this, Sapience Therapeutics, Inc., a US-based biotechnology company focused on research & development on peptide therapeutics announced a research collaboration with the University of Bath (UK) to develop and discover new therapeutic agents for oncology applications. Hence, research collaborations to develop new therapeutic peptides is a major trend in the market. In October 2019, Zealand Pharma A/S, a Denmark-based biotechnology company specializing in the discovery and development of innovative peptide-based medicines acquired Encycle Therapeutics, Inc. for up to $80 million. The acquisition is expected to strengthen the Zealand Pharma A/S in the peptide therapeutics and in targeting gastrointestinal diseases with the addition of orally delivered preclinical macrocycle peptide. Encycle Therapeutics, Inc. is a Canada-based biotechnology company specializing in unique platform technology that allows the synthesis of macrocyclic peptides demonstrating improved drug-like properties. Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. North America was the largest region in the biosimilar therapeutics market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar therapeutic peptides market is segmented - 1) By Route of Administration: Parenteral Route, Transdermal Route, Others 2) By Application: Cancer, Cardiovascular, Central Nervous System, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders 3) By Type: Innovative, Generic

The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA). The main routes of administration in rituximab biosimilar are subcutaneous, intravenous, molecular type. Intravenous therapy is a medical procedure in which fluids, drugs, and nutrients are delivered straight into a patient's vein. The different applications include non-hodgkin’s lymphoma, chronic lymhocytic leukemia, rheumatoid arthritis, others and is distributed through various channels such as hospital pharmacy, online pharmacy, retail pharmacy, other direct distribution channels. The global rituximab biosimilars market size is expected to grow from $1.77 billion in 2021 to $2.05 billion in 2022 at a compound annual growth rate (CAGR) of 16.1%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The rituximab biosimilars market is expected to reach $3.42 billion in 2026 at a CAGR of 13.6%. The rising prevalence of non-Hodgkin's lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin's lymphoma or lymphoma is cancer that starts in white blood cells, lymphocytes that are part of the body’s immune system. According to the American Cancer Society’s, NHL is the most common cancers in the USA accounting for about 4% of all cancers. About 81,560 people (45,630 males and 35,930 females) are diagnosed with NHL in 2021 in the USA. Thus, growing cases of non-Hodgkin's lymphoma is predicted to generate high demand for rituximab biosimilars over the forecast period. The high cost associated with rituximab biosimilars acts as a major restraint for the growth of rituximab’s market over the upcoming years. The cost of the subcutaneous option was costlier than IV biosimilar rituximab. The cost of subcutaneous formulation for patients with small body size is between $3,805 and $8,807 and for medium body size between $325 to $6109 and $484 to $6267 for 2 infusion speeds. The high costs of rituximab biosimilars makes it unaffordable for treatment of patients with low income, hindering the growth of the market. The companies operating in the biosimilars are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships is shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche's Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd. North America was the largest region in the rituximab biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global rituximab biosimilars market is segmented - 1) By Application: Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis, Others 2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels 3) By Route of Administration: Subcutaneous, Intravenous, Molecular Type

The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones. These hormones are used when patients have a drop in hormones in their bodies or are unbalanced. Only goods and services traded between entities or sold to end consumers are included. The main types of biosimilar hormones are teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars and others. Teriparatide is a parathyroid hormone recombinant (PTH). Teriparatide is similar to a component of human PTH, and when taken on a regular basis, it stimulates osteoblasts more than osteoclasts, resulting in an increase in bone mass. The different applications include research and biotechnology, diagnostics, biocatalysts, therapeutics, others and distributed through various channels such as hospital and retail pharmacy, online pharmacy or e-pharmacy, speciality clinics. The global biosimilar hormones market size is expected to grow from $1.74 billion in 2021 to $2.31 billion in 2022 at a compound annual growth rate (CAGR) of 32.5%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar hormones market is expected to reach $6.22 billion in 2026 at a CAGR of 28.1%. The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market. For instance, according to the Italian Journal of Pediatrics, the prevalence of growth hormone deficiency (GHD) in childhood widely varies between 1 out of 3480 and 1 out of 30,000 children annually. In children, the growth hormone can influence bone mineralization and lead to several metabolic effects, including glucose and lipid homeostasis. Annually, about 6,000 adults are diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market. Stringent regulations imposed on the approval of hormone biosimilars limits the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market. Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launch in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products across various locations to boost sales and maximize profits. For instance, in October 2019, Biocon Biologics and Mylan N.V. announced the launch of biosimilar hormones in Australia to treat the polygenic disorder. Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma. The regions covered in the biosimilar hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar hormones market is segmented - 1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Others 2) By Application: Research and Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Others 3) By Distribution Channel: Hospital and Retail Pharmacy, Online Pharmacy/ePharmacy, Speciality Clinics

The biosimilar lymphocyte modulator market consists of sales of immune regulating lymphocyte modulators by entities (organizations, sole traders and partnerships) that manufacture lymphocyte modulator biosimilars. Lymphocyte modulators are intended as an aid in the treatment for cancer and autoimmune diseases, and for regulating carotene intake in humans with a weak immune system. Only goods and services traded between entities or sold to end consumers are included. The main types of drugs in biosimilar lymphocyte modulator market are campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar. Campath is a prescription medication used to treat the symptoms of CLL. Campath can be taken on its own or in combination with other drugs. The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others The global biosimilar lymphocyte modulator market size is expected to grow from $1.16 billion in 2021 to $1.34 billion in 2022 at a compound annual growth rate (CAGR) of 15.4%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar lymphocyte modulator market is expected to reach $2.10 billion in 2026 at a CAGR of 11.8%. Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulator market. The combination of immunotherapies or pairing of immunotherapies with other types of cancer treatments such as chemotherapy or radiation enhances the benefit associated with lymphocyte modulators. According to a study conducted by the researchers at Washington University School of Medicine in St. Louis, combining two immunotherapy strategies into one can give better results for certain blood cancers such as leukaemia. Evidence suggests that this new approach could be safer with reduced side effects than other cellular immunotherapies such as CAR-T cell. The combination approach, therefore, saves patients’ life from a life-threatening reaction of the immune system thereby driving the growth of the lymphocyte modulator market. The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market. Drug shortages are due to several factors including challenges for acquiring raw materials, manufacturing problems, regulatory issues, business decisions, and numerous disturbances within the supply chain. They adversely affect patient care by causing the replacement of safe and effective therapies with elective medicines, compromising or delaying medical procedures, or causing medication errors. For instance, in January 2019, the American Society of Haematology, an association comprising of clinical scientists and physicians that provides care to patients in diverse settings, sent a letter to USFDA highlighting the issue of shortage of critical hematologic drugs such as etoposide and methotrexate, which have no alternatives. Mainly the drug etoposide, which is a chemotherapeutic drug, that is a crucial component in treatment regimens designed to be curative for life-threatening conditions including leukaemia and lymphomas. Due to the shortage, some patients have received less effective treatment. Thus, the raw material shortages cause delayed and compromised medical treatments and also results in limiting the growth of the market. Tumor-Infiltrating Lymphocyte Immunotherapy has been gaining popularity in recent times because of its positive results in anti-cancer treatments. Tumor-infiltrating lymphocytes (TILs) comprise of all lymphocytic cell populaces that have occupied the tumor tissue. TILs have been depicted in various solid tumors including breast cancer, and are emerging as a significant biomarker in predicting the efficacy and result of treatment. Due to promising results, many companies have started launching TIL technologies. For instance, in January 2020, Lovance Biotherapeutics, a US-based start-up company, has licensed TALEN technology from Cellectis to develop gene-editing tumor-infiltrating lymphocytes (TIL) to treat several cancer indications. Other companies investing in TIL technology are Optera Therapeutics Corp and TILT Biotherapeutics. In July 2020, Cytocom, Inc., a US-based immunotherapy generating company, announced the acquisition with ImQuest Life Sciences, Inc. for an undisclosed sum. The deal is expected to support Cytocom’s vision of strategic growth and strengthen internal drug development programs with new assets and secured revenue-generating operations, scientific resources, and tools and capacity. ImQuest Life Sciences is a US-based company with leading drug discovery and development. The company was founded in 2004. Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis, and Celltrion. North America was the largest region in the biosimilar lymphocyte modulator market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the biosimilar lymphocyte modulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar lymphocyte modulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilar lymphocyte modulator market is segmented - 1) By Drug: Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar 2) By Disease: Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis, Others

The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceuticals that are manufactured using cell lines and offer no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired. The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases and others. The global biosimilars market size is expected to grow from $15.67 billion in 2021 to $19.10 billion in 2022 at a compound annual growth rate (CAGR) of 21.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar market is expected to reach $42.30 billion in 2026 at a CAGR of 22%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market. The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of familiarity with biosimilars reduces the likelihood of prescribing the drugs to patients which affects the demand for new biosimilars in the market. For instance, according to the PwC’s Health Research Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians and specialists restricts the growth of the biosimilars market. Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in 2019, Mylan, a U.S-based pharmaceutical company, in partnership with Biocon, an Indian based biopharmaceutical company launched biosimilar insulin glargine named Semglee. Also, in 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the biosimilars market are investing in the development of insulin biosimilar to gain profits. Major players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, STADA Arzneimittel, Sandoz International, Samsung Bioepis, Teva Pharmaceuticals, Apotex, AMEGA Biotech S.A., Bioton S.A., Innovent Biologics International, Allergan plc, BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupin Merck, Novartis, Ratiopharm, Wockhardt, Zydus Cadila, Allergan Plc., Hospira International., Actavis International., Johnson & Johnson and Roche. North America was the largest region in the biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biosimilars market is segmented - 1) By Product: Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins 2) By Type: Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Others 3) By Application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Others

The oncology biosimilars market consists of sales of medicine and drug related products for cancer treatment. Biosimilars are pharmaceuticals which are manufactured using cell lines and are exclusive to the manufacturer. The manufacturing of these cell line processes is a complex and time-consuming process. The main drug types of oncology biosimilars are monoclonal antibody, immunomodulators, hematopoietic agents and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, others and the various distribution channel involved are hospital pharmacy, retail pharmacy and online pharmacy. The global oncology biosimilars market size is expected to grow from $3.27 billion in 2021 to $4.19 billion in 2022 at a compound annual growth rate (CAGR) of 28.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oncology biosimilars market is expected to reach $11.35 billion in 2026 at a CAGR of 28.3%. The expiration of patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms which induces the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offers the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars. The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of detailed awareness on the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians and specialists restricts the growth of the oncology biosimilars market. The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting growth potential of rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus' plan is to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up R&D facility to boost biosimilar development. Major players in the oncology biosimilars market are Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan and F Hoffmann-La Roche. North America was the largest region in the oncology biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global oncology biosimilars market is segmented - 1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Others 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Filgrastim Biosimilars Market Definition